101015162

29E

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an ericalope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

Docket No. GJE-18D1 Patent No. 6,919,067

Pace, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

policants

Aaron Gershon Filler, Andrew Michael Lindsay Lever

Íssued

July 19, 2005

Patent No.

6,919,067 B2

For

Compositions Comprising a Tissue Glue and Therapeutic Agents

Mail Stop Certificate of Corrections Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Certificate
AUG 2 4 2005

of Correction

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction (in duplicate) for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

Patent Reads:

Application Reads:

Title page (73) Assignee:

<u>Title page (73) Assignee:</u>

"Syngenix Limited (GB)"

-- Molecular Synthetics Limited (GB)--

Column 3, line 32:

Page 5, line 7:

"comprises; a"

--comprises a--

Column 4, lines 22-23:

Page 6, line 28:

"08/087,78:L"

--08/087,781--

<u>Column 4, line 46</u>:

Page 7, lines 15-16:

"t=64 hours, 1-, 2.283 MeV"

 $--t^{1/2}$ = 64 hours, β -, 2.283 MeV--

Column 5, line 55:

Page 9, line 19:

"the Y-ferrites"

--the ⁹⁰Y-ferrites--

Column 5, line 65:

Page 9, line 30:

"the Y will be"

--the ⁹⁰Y will be--

Column 7, line 31:

Page 12, line 25:

"of Fe-enriched"

--of ⁵⁶Fe-enriched--

Column 7, line 51:

Page 13, line 9:

"1F"

--¹⁸F--

Column 7, line 56:

Page 13, line 14:

"of F in"

--of ¹⁸F in--

Column 15, lines 21-22:

Page 27, line 27:

"temperatures; tend"

--temperatures tend--

<u>Column 15, line 57:</u>

Page 28, line 29:

"22 mM"

--20 mM--

Column 16, line 3:

Page 29, line 7:

"21D µl"

--20 µl--

Column 16, line 67 to Column 17, line 1:

Page 30, lines 35-37, through to Page 31, line 7:

"manifold 18 dividing barrelled needle sets"

--manifold 18 dividing flow of glue components into four sets and then pairing up the sets of double-barrelled needles, one pair of needles shown at 19 emerging from manifold cover to enter the plunger shaft, and, shown at 20, a fully-extended set of double-barrelled needles spreading out from sheath tip to penetrate tumor in various directions. Fig. 3J shows the plunger lifted to withdraw needles back into the sheath. Fig. 3K shows the plunger advanced to force the four doublebarrelled needle sets--

Column 18, line 23:

Page 36, original claim 14, line 1 (renumbered

as claim 10):

"radionucide"

--radionuclide--

<u>Column 18, line 25:</u>

Page 36, original claim 15, line 1 (renumbered

as claim 11):

"radionucide"

--radionuclide--

Column 18, line 50:

Page 36, original claim 17, line 4:

"radionucide"

--radionuclide--.

A true and correct copy of pages 5-7, 9, 12, 13, 27-31, and 36 of the specification as filed and a copy of the Notice of Recordation of Change of Name document (Syngenix Limited to Sirus Pharmaceuticals, Ltd.) and a copy of the Notice of Recordation of Assignment document (Sirus Pharmaceuticals, Ltd. to Molecular Synthetics Limited) which support Applicants' assertion of the errors on the part of the Patent Office accompanies this Certificate of Correction.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,

Doran R. Pace

Patent Attorney

Registration No. 38,261

Phone No.:

352-375-8100

Fax No.:

352-372-5800 P.O. Box 142950

Address: P

Gainesville, FL 32614-2950

DRP/sl

Attachments: Copy of pages 5-7, 9, 12, 13, 27-31, and 36 of the specification

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,919,067 **B2**

Page 1 of 2

APPLICATION NO.:

10/015,162

DATED

July 19, 2005

INVENTORS

Aaron Gershon Filler, Andrew Michael Lindsay Lever

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item (73) Assignee,

"Syngenix Limited (GB)" should read -- Molecular Synthetics Limited (GB)--.

Column 3,

Line 32, "comprises; a" should read --comprises a--.

Column 4,

Lines 22-23, "08/087,78:" should read --08/087,781--.

Line 46, "t=64 hours, 1-, 2.283 MeV" should read --t $^{1/2}$ =64 hours, β -, 2.283 MeV--.

Column 5,

Line 55, "the Y-ferrites" should read --the ⁹⁰Y-ferrites--.

Line 65, "the Y will be" should read --the ⁹⁰Y will be--.

Column 7,

Line 31, "of Fe-enriched" should read --of ⁵⁶Fe-enriched--.

Line 51, "1F" should read -- 18F--.

Line 56, "of F in" should read --of ¹⁸F in--.

Column 15,

Lines 21-22, "temperatures; tend" should read --temperatures tend--.

Line 57, "22 mM" should read --20 mM--.

MAILING ADDRESS OF SENDER: Saliwanchik, Lloyd & Saliwanchik P.O. Box 142950 Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO.

6,919,067 β_{2}

Page 2 of 2

APPLICATION NO.:

10/015,162

DATED

July 19, 2005

INVENTORS

Aaron Gershon Filler, Andrew Michael Lindsay Lever

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16,

Line 3, "21D μ l" should read --20 μ l--.

Column 16,

Line 67, to Column 17, line 1, "manifold 18 dividing barrelled needle" should read --manifold 18 dividing flow of glue components into four sets and then pairing up the sets of double-barrelled needles, one pair of needles shown at 19 emerging from manifold cover to enter the plunger shaft, and, shown at 20, a fully-extended set of double-barrelled needles spreading out from sheath tip to penetrate tumor in various directions. Fig. 3J shows the plunger lifted to withdraw needles back into the sheath. Fig. 3K shows the plunger advanced to force the four double-barrelled needle sets--.

Column 18,

Line 23, "radionucide" should read --radionuclide--.

Line 25, "radionucide" should read --radionuclide--.

Line 50, "radionucide" should read --radionuclide--.

MAILING ADDRESS OF SENDER: Saliwanchik, Lloyd & Saliwanchik P.O. Box 142950 Gainesville, FL 32614-2950